This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Michel Janicot
Chief Development Officer at InteRNA Technologies


Michel holds a Ph.D. degree in Biochemistry (Molecular and Cellular Biology) from University Paris VII (France) and was Postdoctoral Fellow at The Johns Hopkins University (Baltimore, MD. USA). He has over 35 years of professional experience in Oncology preclinical and early clinical pharmaceutical drug development in increasing leadership roles at Rhone-Poulenc Rorer (Sanofi) and Janssen (Johnson & Johnson). Michel has a long-lasting hands-on experience and strategic expertise and multidisciplinary network in the discovery and development of RNA-based therapeutics (mRNAs, miRNA/siRNAs, and ASOs) with strategic focus in oncology therapeutic intervention.

Agenda Sessions

  • Preclinical to Clinical Transition with INT-1B3 (LNP-formulated miRNA-193a-3p mimic): Translational Medicine Perspectives for Advanced Cancer Patients